Lixiana OD tablets 60 mg for treatment of recurrence of venous thromboembolism (edoxaban tosylate hydrate, deep venous thrombosis, pulmonary thromboembolism)

General information on Japanese Lixiana OD tablets 60 mg for treatment and prevention of recurrence of venous thromboembolism (edoxaban tosylate hydrate, deep venous thrombosis, pulmonary thromboembolism)

Package details: 100 tablets

Manufacturer: Daiichi Sankyo, Co., Ltd., Japan

Active ingredient: edoxaban tosylate hydrate (chemical formula C24H30ClN7O4S)

Medical effect: Lixiana OD tablets are effective for treatment and prevention of the recurrence of venous thromboembolism (deep venous thrombosis and pulmonary thromboembolism).

Contraindications and precautions: do not use in the following categories of patients:

• patients with bleeding (intracranial bleeding, retroperitoneal bleeding or bleeding in other critical organs),
• patients with bleeding tendency (bleeding disorders, gastrointestinal ulcers, diabetic retinopathy, etc.),
• patients with acute bacterial endocarditis,
• patients with renal failure, liver dysfunction or liver disease with coagulation disorder,
• patients with body weight less than 40 kg,
• pregnant or breastfeeding women.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Please note that there should be 12 hours or more before taking the next scheduled dose of this medicine.

Dosage and administration of Lixiana OD tablets 60 mg from Japan for treatment and prevention of recurrence of venous thromboembolism

For adults with body weight of 60 kg or less: take 30 mg of edoxaban at a time, once a day.

For adults with body weight of more than 60 kg: take 60 mg of edoxaban at a time, once a day. The dosage may be decreased to 30 mg of edoxaban at a time, once a day according to patient’s renal function and concomitant medications.

Please note that this medicine contains 60 mg of edoxaban in a tablet.

This medicine dissolves in saliva being placed on the tongue. It can be taken with or without water, but it should not be taken without water when the patient is lying down.

How effective are Lixiana OD tablets 60 mg from Japan for treatment and prevention of recurrence of venous thromboembolism?

Lixiana OD tablets contain edoxaban tosylate hydrate, a monohydrate of the tosylate salt of edoxaban, a monocarboxylic acid amide, a chloropyridine, a thiazolopyridine and a tertiary amino compound. This new medicine works by inhibiting EC 3.4.21.6 (coagulation factor Xa) in the coagulation pathway, inhibiting platelet aggregation and suppressing blood coagulation. As the result, Lixiana OD tablets help to prevents and thromboembolism caused by blood coagulation in blood vessels.

Who should take Lixiana OD tablets 60 mg from Japan?

Lixiana OD tablets are effective for the reduction of the risk of ischaemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for treatment and prophylaxis of the relapse of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism) and for the reduction of the risk of venous thromboembolism in patients undergoing the orthopedic surgeries for the lower limbs. Clinical studies showed that while edoxaban is as good as warfarin for the prevention of stroke and systemic embolism, edoxaban treatment also provides significant reductions in the risk of hemorrhagic stroke, cardiovascular mortality, major bleeding and intracranial bleeding (H. Bounameaux, A. J. Camm. “Edoxaban: an update on the new oral direct factor Xa inhibitor”. Drugs, 2014, July, 74(11): 1209-31).